Monserrat Muñoz - 1Medical Oncology Department, Hospital Clinic of Barcelona

基本信息

浏览量：16

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 34 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

55P Clinicopathological and molecular changes induced by neoadjuvant therapy (NAT) in hormone receptor-positive (HR+)/HER2-low vs HER2 0 breast cancer (BC)

F. Schettini, T. Pascual, L. Ghiglione, F. Brasó-Maristany, O. Martínez-Sáez,B. Conte, I. Cebrecos, E. Mension, S. Ganau,E. Sanfeliu Torres, B. Gonzalez-Farre, P. Jares,

ESMO Openno. 1 (2023): 101279-101279

引用0浏览0引用

8P First decision impact study of HER2DX in patients (pts) with HER2-positive (HER2+) early breast cancer

O. Martinez Saez, F. Brasó-Maristany, M. Marín-Aguilera,M.J. Vidal Losada, B. Adamo, T. Pascual, F. Schettini,B. Conte, N. Chic,R. Gomez Bravo, I. Garcia Fructuoso,E. Segui Solis,

ESMO Openno. 1 (2023): 101232-101232

引用0浏览0引用

10P HER2 loss and PAM50 dynamics after neoadjuvant therapy (NAT) in HER2-positive (HER2+) early breast cancer (BC)

S. Morganti, F. Brasó-Maristany,M. Rey, G. Goberna, T. Pascual, F. Schettini,B. Conte,R. Gomez Bravo, I. Garcia Fructuoso,E. Segui Solis, P. Galván,E. Sanfeliu Torres,

ESMO Openno. 1 (2023): 101234

引用0浏览0引用

Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancer

G Villacampa, N M Tung, S Pernas, L Paré, C Bueno-Muiño, I Echavarría, S López-Tarruella, M Roche-Molina, M Del Monte-Millán, M Marín-Aguilera, F Brasó-Maristany, A G Waks,

Annals of oncology : official journal of the European Society for Medical Oncologyno. 9 (2023): 783-795

引用0浏览0WOS引用

275P Clinical and molecular impact of neoadjuvant chemotherapy (NACT) or endocrine therapy (NET) on hormone receptor positive (HR+)/HER2-negative (-) breast cancer (BC)

F. Schettini, F. Brasó-Maristany, T. Pascual, P. Galván, B. Conte, L. Ghiglione, C. Falato, O. Martínez-Sáez, N. Chic,A.B. Rodriguez,E. Sanfeliu Torres, B. Gonzalez-Farre,

Annals of Oncology (2023): S294-S294

引用0浏览0引用

5P HER2DX risk-score in HER2-positive (HER2+) breast cancer following neoadjuvant and adjuvant anti-HER2-based treatment: An updated survival analysis

O. Martinez Saez, F. Brasó-Maristany, G. Griguolo,L. Pare Brunet,M.V. Dieci,J. Cortés,A. Llombart Cussac, G. Villacampa, M. Marín-Aguilera,M. Rey, G. Goberna,M. Munoz,

ESMO Openno. 1 (2023): 101229-101229

引用0浏览0引用

Clinical outcomes in patients with germline pathogenic variants in homologous recombination repair (HRR) genes treated with CDK4/6 inhibitors (CDK4/6i) and endocrine therapy (ET)

A. Rodriguez Hernandez,O. Martinez Saez, F. Braso-Maristany, B. Pastor, M. Potrony,L. Moreno, E. Grau, J. A. Puig-Butille,A. Sanchez, F. Schettini,B. Conte,N. Chic,

ANNALS OF ONCOLOGY（2022）

引用0浏览0引用

132TiP HCB-ONC001 ELPIS TRIAL: Omission of surgery and sentinel lymph node dissection in clinically low-risk HER2-positive breast cancer with high HER2 addiction and a complete response following standard anti-HER2-based neoadjuvant therapy

T. Pascual, N. Chic,O. Martinez Saez,E. Sanfeliu Torres, B. Adamo, I. Cebrecos, E. Mension, X. Bargalló, X. Caparros, S. Ganau, B. Gonzalez-Farre,M. Mollá,

Annals of Oncology（2022）

引用3浏览0引用

Breast cancer in women with germline pathogenic variants: Frequency, clinical behavior, and outcomes of a series of patients from Spain

A. Rodriguez Hernandez,F. Braso Maristany, B. Pastor, M. Potrony,L. Moreno, E. Grau,J. A. Puig-Butille,O. Martinez Saez,B. Conte,N. Chic,M. J. Vidal Losada,M. Munoz,

ANNALS OF ONCOLOGY（2022）

引用0浏览0引用

147P Breast cancer in women with germline pathogenic variants: Frequency, clinical behavior, and outcomes of a consecutive series of patients from Spain

A. Rodriguez Hernandez,F. Braso Maristany, B. Pastor, M. Potrony,L. Moreno, E. Grau, J.A. Puig-Butille,O. Martinez Saez,B. Conte,N. Chic,M.J. Vidal Losada,M. Munoz,

Annals of Oncology (2022): S188-S188

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn